TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05320081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD30 CAR-T
Description: Subjects need to complete a series of checks before reinfusion of CD30 CAR-T cells as baseline information for subjects after non-myeloablative pretreatment. The subject was reinfused with CD30 CAR-T cells (10±3)×10\^6/kg on the 0th day of the first dosing cycle (the investigator decided the specific reinfusion dose based on the subject's own/disease conditions and preparation conditions in vitro ), concurrent oxygen inhalation and monitoring (ECG, blood pressure and blood oxygen monitoring). The reinfusion was completed in about 30 minutes, and the tube was flushed with saline.~Note: CAR-T cell infusion and reinfusion dose are based on the subject's condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Received Camrelizumab treatment on the 15th day after CAR-T cell reinfusion, and then received Camrelizumab treatment every 2 weeks.
Study: NCT06104085

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-MY6349 SPECT/CT scan
Description: Triple-negative breast cancer patients underwent 99mTc-MY6349 SPECT/CT imaging to observe the binding ability of this tracer to Trop2 in the tumor and the uptake of the drug by the tumor, combined with the pathological expression level of Trop2 in the patient's lesions and 18F-FDG PET/CT imaging uptake to evaluate the efficacy of 99mTc-MY6349 in the diagnosis of triple-negative breast cancer; at the same time, combined with the treatment effect of patients using the anti-Trop2 targeted antibody gosatuzumab, the analysis of 99mTc-MY6349 SPECT/CT imaging prediction of prognosis in patients with triple-negative breast cancer treated with gosatuzumab.
Study: NCT06185374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Instructions/Motivation
Description: For instructional messages, earlier messages will remind patients of the colonoscopy appointment and later messages will help patients complete the bowel preparation process in real-time. Motivational messages will be sent along with instructional messages.
Study: NCT05230628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TENS
Description: Active TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS
Description: Sham TENS stimulation will occur daily for 10 minutes, 3-4 times a day, 30 minutes before the main meals. The duration will be 6 months for each patient.
Study: NCT05221411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil will be started at a dose 500mg twice daily. When tolerated and an AUC within range, patients will be titrated to 1000mg twice daily at week two.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Meltdose tacrolimus will be started at a dose of 0.07 mg/kg/day. The drug will be taken orally once-daily in the morning. Dose will be adjusted to reach target AUC and trough levels.
Study: NCT06066216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Injectable solutionS
Study: NCT04549285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs)
Description: Human Umbilical Cord Tissue-derived Mesenchymal Stromal Cells (hCT-MSC):~hCT-MSCs is an allogeneic cell product manufactured from donated umbilical cord tissue that is digested and expanded in culture, cryopreserved and banked. Doses contain 2x10\^6 cells/kg (up to a maximum dose of 100x10\^6 cells) diluted in plasmalyte-A with 5% HSA to a volume of 20-40mL.
Study: NCT06117735

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic shunt
Description: The experimental device is a class III implanted shunt device, which will be used to create a shunt between intrahepatic and portosystemic to reduce portal hypertension.
Study: NCT04782063

Intervention type: OTHER
Group type: OTHER
Intervention: Calibration of infant breast milk and formula milk intake
Description: We will calibrate (reduce) the pumped breast milk or formula intake of infants of overweight and obese mothers who exceed 75%ile of WHO BMI, in order to prevent infant obesity and subsequent childhood obesity.
Study: NCT05244512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-based leadership training
Description: 7-modules online training over six months mentored by tutors. Independent familiarisation of reading material, peer-group discussions, self-reflection, assignments, tutor's feedback.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional training
Description: 7-modules online training over six months. Independent reading only.
Study: NCT04730765

Intervention type: PROCEDURE
Intervention: left elective colectomy (Surgical Experimental Group)
Description: Conventional laparoscopic resection of the sigmoid colon is performed using four ports. The left colon is mobilised from the lateral side along Gerota's fascia. The splenic flexure is mobilised at the discretion of surgeons. The mesentery of the sigmoid colon is then medially fenestrated at the promontory level. The superior rectal artery as well as the inferior mesenteric artery and vein are identified and are cut using tissue-sealing devices. A linear stapler device is applied for division of the large intestine. The sigmoid is retracted through a Pfannenstiel incision or enlargement of the left lower abdominal incision. Colorectal anastomosis is performed using a double stapling technique following open resection of the affected colon.

Intervention type: DRUG
Intervention: antibiotic therapy (medical Control Group)
Description: Antibiotic treatement for 10 days by oral or intravenous administration
Study: NCT04421170

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone app for smoking cessation
Description: Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks.
Study: NCT06052228

Intervention type: OTHER
Intervention: Assessment Group
Description: Evaluation forms will be applied to the participant who meets the inclusion criteria by face-to-face interview method. The sociodemographic information of the participants and the time taken to answer the questions in the questionnaires will vary according to each participants but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1-week intervals.
Study: NCT02828761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Calcium Scoring
Description: Scan with 64-detector row or better CT scanners with quantification by the Agatston method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
Study: NCT04736914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP/R-DHAOx； Zanubrutib（induction）； ASCT conditioning ； Zanubrutinib（Maintenance）
Description: Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAOx (cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~* Zanubrutinib, 160mg PO BID, continuously for 2 year or until progressive disease。~* Zanubrutinib maintenance will start after regeneration of peripheral blood count after the end of the last cycle of induction therapy or ASCT
Study: NCT04983966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desﬂurane
Description: General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: General anesthesia for patients will be inducted and maintained with desflurane inhalation and remifentanil infusion.~Remimazolam group will be started with remiamazolam at 6 mg/kg/h and TCI Minto model of remifentanil for the time of anesthesia induction, and maintained at 0.5
Study: NCT05022186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oil
Description: Patients will use it with specific instructions and they will be monitored at least one time in a month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homotaurine
Description: Patients will use it with specific instructions and they will be monitored at least one time in a month
Study: NCT04959747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: Body acupuncture will choose eight acupoints as Yingxiang (LI20),Shangxing (GV23), BiTong, Yintang, Hegu. Disposable acupuncture needle (0.25 mm in diameter and 25-30mm in length) are inserted at a depth of 10-25 mm obliquely into scalp acupuncture points (ShangXing, YinTang) and straightly into face/body acupuncture points (Yingxiang, BiTong, Hegu).~We will also deliver electro-acupuncture will be applied to the face points at fast and dispersed waves through electric needle stimulator which is provided by Chinese Medicine Clinic (ES-160 6-Channel Programmable electro-acupuncture) for 30 minutes.
Study: NCT04999839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858 study drug
Description: NDI-034858 2 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858 study drug
Description: NDI-034858 5 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858 study drug
Description: NDI-034858 15 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-034858 study drug
Description: NDI-034858 30 mg (2\*15 mg) oral capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to NDI-034858 oral capsules.
Study: NCT05003037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
Description: Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Toripalimab,Pemetrexed,Carboplatin/Cisplatin
Description: Surufatinib at the dose determined in phase safety lead-in，250 mg，qd，po，every 3 weeks(q3w) ; Toripalimab at the dose 240mg，iv, d1, given every 3 weeks (q3w); Pemetrexed at the dose 500 mg/m2，iv，d1，given every 3 weeks (q3w); Carboplatin at the dose AUC=5\~6，iv，d1，given every 3 weeks (q3w) or Cisplatin at the dose 75 mg/m2，iv ,d1，q3w; Maintenance treatment：After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D，d1-21，q3w＋Toripalimab 240mg，d1，q3w+Pemetrexed 500mg/m2，d1，q3w was taken until the disease progressed.
Study: NCT05841368

Intervention type: DIAGNOSTIC_TEST
Intervention: CAM-ICU
Description: Delirium in adult patients will be screened according to CAM-ICU

Intervention type: DIAGNOSTIC_TEST
Intervention: pCAM-ICU
Description: Delirium in adult patients will be screened according to pCAM-ICU
Study: NCT06317558

Intervention type: DRUG
Intervention: Neoadjuvant immunotherapy
Description: Immune checkpoint inhibitors are used as neoadjuvant settings for NSCLC patients.

Intervention type: DRUG
Intervention: Other drugs for neoadjuvant treatment
Description: Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
Study: NCT06059365

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hospitalization
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). In this group, were admitted in the hospitalization ward

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: Once the patient was operated and an uncomplicated appendicitis was confirmed, the patient was randomized to one of the two experimental branches: the hospitalization group (HG) or outpatient group (OG). Patients in the OG were referred to the day- surgery unit where they were discharged according to ALDRETE criteria.
Study: NCT05309915

Intervention type: DRUG
Group type: OTHER
Intervention: STP707
Description: STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Intervention type: DRUG
Group type: OTHER
Intervention: STP707
Description: STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Intervention type: DRUG
Group type: OTHER
Intervention: STP707
Description: STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.

Intervention type: DRUG
Group type: OTHER
Intervention: STP707
Description: STP707 Powder for Injection, contains 2 (siRNA) and (HKP+H) delivery system.
Study: NCT06240637

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemonitoring
Description: A networked platform that enables the telemonitoring of both compliance data and the patient's ventilatory pattern, allowing the assessment of flow/pressure curves as well as leaks or events related to the upper airway.
Study: NCT04653480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: 250mg per oral, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3mg/kg IV, once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: oxaliplatin or irinotecan based regimens, according to the first line treatment
Study: NCT06477159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Capsules
Description: Treatment with Pancreatic Enzyme Replacement Therapy
Study: NCT02522247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UPP
Description: surgery with cold steel in general anesthesia
Study: NCT06236100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengthening Families Program + Family Advocate
Description: This intervention will integrate clinically trained, trauma-informed Family Advocates (FA) into the established, evidence-based Strengthening Families Program (SFP). Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks. FAs will assist families in accessing community resources for substance use and Adverse Childhood Experiences (ACE) prevention and treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthening Families Program
Description: This intervention consists of the SFP7-17 Group Class Curriculum. Families will participate in the SFP7-17 curriculum, which consists of 11 sessions over 10-14 weeks.
Study: NCT06110663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10241+ Almonertinib
Description: HS-10241 300mg twice daily (BID) combined with Almonertinib 110mg once daily (QD) orally, for every cycle of 21 days until disease progression or other criteria for treatment discontinuation will be met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Cisplatin /Carboplatin
Description: The standard chemotherapy treatment of cisplatin/carboplatin combined with pemetrexed for 4\~6 cycles (every 3 weeks).~Participants will continue receive pemetrexed monotherapy until disease progression or other criteria for treatment discontinuation will be met.
Study: NCT05085886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DepCare
Description: Primary Care Provider (1) One-time presentation or video with education and motivational messaging around collaborative care, functionality of the DepCare patient tool and optimal management of depression and comorbid anxiety (2) Quality improvement/ implementation team meetings on optimizing mental health treatment in primary care and DepCare (i.e., multi-level, multi-component intervention) implementation (3) Automatically-generated decisional support on individual patient treatment preferences (i.e., for every patient who receives the DepCare patient tool) Patient: Tool comprised of enhanced depression and anxiety screening (includes option for voice-over questions, point-and-click responses), and for those who screen positive for depressive symptoms (with or without comorbid anxiety), diagnosis recognition support, psycho-education, videos promoting patient engagement in treatment, and personalized medication selection support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Clinic-level (1) Quality Improvement Support and education around valid depression screening (2) Local technical support for mental health treatment optimization
Study: NCT06091696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: inspiratory muscle training will be done by using a pressure threshold loading device (Threshold Inspiratory Muscle Training, Respironics, Pittsburg, PA, USA). By using a spring-loaded one-way valve, this device provides air flow-independent resistance to inspiration at a detectable intensity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercises
Description: Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Exercise training sessions under the supervision of an experienced physiotherapist were conducted for 30 minutes, 3 times per week, with intensity ranging between 13 and 15 on the rated perceived exertion scale (RPE).
Study: NCT04770532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin degludec
Description: Participants will receive subcutaneous (s.c.) injections of insulin degludec once daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Icodec
Description: Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 26 weeks
Study: NCT05885087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley or balloon catheter
Description: Three Foley balloon catheters attached side by side were inflated with 60mls each and a gentle traction of 250mls water applied.
Study: NCT05696249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OhmTrak device.
Description: All probands will undergo six-week outpatient therapy once a week. The intervention group will be equipped with an OhmTrak device for home self-therapy and instructed in its correct use at least 5 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Physiotherapy
Description: All probands will undergo six-week outpatient therapy once a week for an hour

Intervention type: OTHER
Group type: OTHER
Intervention: Outpatient Physiotherapy
Description: All probands will undergo six-week outpatient therapy once a week for an hour
Study: NCT05139043

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO